We are live on ! Find out more
ZYNE

Zynerba Pharmaceuticals, Inc
ZYNE

Delisted

ZYNE was delisted on the 10th of October, 2023.

Back to rankings

60 hedge funds and large institutions have $70.5M invested in Zynerba Pharmaceuticals, Inc in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,450% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 2

118% more capital invested

Capital invested by funds: $32.3M → $70.5M (+$38.1M)

78% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 9

76% more funds holding

Funds holding: 34 → 60 (+26)

28% more call options, than puts

Call options by funds: $10.7M | Put options by funds: $8.4M

Holders
60
Holders Change
+26
Holders Change %
+76.47%
% of All Funds
1.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
16
Reduced
9
Closed
2
Calls
$10.7M
Puts
$8.4M
Net Calls
+$2.33M
Net Calls Change
-$1.03M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$6.69M
2
BlackRock
BlackRock
New York
+$3.94M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.96M
4
SFM
Sphera Funds Management
Israel
+$1.99M
5
GPCM
Granite Point Capital Management
Massachusetts
+$1.97M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$11.7M
2
JGC
J. Goldman & Co
New York
-$376K
3
PI
Putnam Investments
Massachusetts
-$368K
4
VKH
Virtu KCG Holdings
New York
-$218K
5
BCM
Bridgeway Capital Management
Texas
-$179K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
26
Laurion Capital Management
New York
$586K +$579K +29,154 New
PI
27
Putnam Investments
Massachusetts
$562K -$368K -18,534 -40%
Northern Trust
28
Northern Trust
Illinois
$525K +$36.9K +1,859 +8%
Simplex Trading
29
Simplex Trading
Illinois
$467K +$350K +17,622 +313%
DTL
30
Dynamic Technology Lab
Singapore
$410K +$406K +20,407 New
SCM
31
Segantii Capital Management
Hong Kong
$291K +$288K +14,500 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$245K +$12.6K +635 +6%
Barclays
33
Barclays
United Kingdom
$209K +$207K +10,400 New
AGM
34
Alpine Global Management
New York
$209K +$207K +10,402 New
SSA
35
Schonfeld Strategic Advisors
New York
$205K +$202K +10,162 New
SC
36
Sculptor Capital
New York
$193K +$191K +9,600 New
SG Americas Securities
37
SG Americas Securities
New York
$188K +$186K +9,364 New
FMA
38
FNY Managed Accounts
New York
$180K +$179K +9,000 New
FPF
39
FNY Partners Fund
New York
$90K +$29.8K +1,500 +50%
Bank of America
40
Bank of America
North Carolina
$89K +$87.6K +4,410 New
UBS Group
41
UBS Group
Switzerland
$78K -$18.5K -932 -19%
Citigroup
42
Citigroup
New York
$33K +$12.5K +630 +63%
AG
43
Advisor Group
Arizona
$25K +$9.94K +500 +68%
LTFS
44
Ladenburg Thalmann Financial Services
Florida
$25K +$23K +1,158 +1,158%
GWM
45
Geneos Wealth Management
Colorado
$20K – – –
Wells Fargo
46
Wells Fargo
California
$14K -$4.05K -204 -23%
IA
47
IFP Advisors
Florida
$11K -$66.8K -3,360 -86%
AIM
48
Acrospire Investment Management
Illinois
$11K +$8.76K +441 +420%
GT
49
Glenmede Trust
Pennsylvania
$10K – – –
MWM
50
MinichMacGregor Wealth Management
New York
$10K +$1.99K +100 +25%
1
2
3

ZYNE Hedge Fund Activity: Q1 2017 in Review

60 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2017, worth a combined $70.5M — up 118% from $32.3M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new ZYNE positions and 2 closed out — a net gain of 29 holders — while 16 added to existing stakes and 9 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $6.69M. The largest seller was Perceptive Advisors, cutting an estimated $11.7M.

  • 60 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2017, up from 34 in Q4 2016.
  • Funds reported $70.5M of Zynerba Pharmaceuticals, Inc stock for Q1 2017, up 118% quarter-over-quarter.
  • 31 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2017 and 2 closed out, a net change of +29 holders.
  • The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2017 was Citadel Advisors, an estimated $6.69M added.
  • The largest Zynerba Pharmaceuticals, Inc seller in Q1 2017 was Perceptive Advisors, an estimated $11.7M sold.

Based on aggregated 13F filings for Q1 2017.